New board member for Silence Therapeutics
October 16, 2017Silence Therapeutics has made a new appointment to its board of directors, in a significant moment in the transition of Silence.
Namely, Dr. Annalisa Jenkins, MBBS, FRCP, CEO of Dimension Therapeutics, Inc. has been named as Chair of Silence’s Board of Directors. Her appointment as Non-Executive Chair is effective Monday, October 16, 2017, on which date Dr. Stephen Parker, the company’s Non-Executive Chairman since September 2015 will become a Non-Executive Director.
Dr. Jenkins is also a committee member of the Science Board to the FDA, serves on the advisory board of the Center for Talent Innovation (U.K.) and is on the Advisory Panel of the Healthcare Businesswomen’s Association.
Ali Mortazavi, Chief Executive Officer of Silence Therapeutics, said that Jenkins’s appointment is a significant moment in the transition of Silence to a fully-integrated biopharma company. He said that her experience will prove to be invaluable. „It is a testament to the progress made at Silence that we have been able to attract Annalisa to our Board,“ he said.
Dr. Annalisa Jenkins said: “Given the recent advances in delivery and chemistry in the RNAi field, I am now of the belief that gene silencing will be a major new drug modality. I believe that Silence’s technology and IP represent a significant opportunity in the next generation of drugs that will potentially transform the treatment of serious diseases with significant unmet medical need, specifically where the liver is the primary target organ. These disorders often have devastating outcomes for patients and their families, and I look forward to contributing to the Company’s advancement of these promising product candidates towards the clinic.”